Literature DB >> 25679012

The role of HER-2 in Breast Cancer.

Takashi Ishikawa1, Yasushi Ichikawa1, Daisuke Shimizu1, Takeshi Sasaki1, Mikiko Tanabe1, Takashi Chishima1, Kazuaki Takabe1, Itaru Endo1.   

Abstract

Entities:  

Year:  2014        PMID： 25679012      PMCID： PMC4323095     

Source DB:  PubMed          Journal:  J Surg Sci        ISSN： 2333-4703


× No keyword cloud information.
  28 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

2.  Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?

Authors:  Kathleen I Pritchard
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

3.  Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Authors:  Minna Tanner; Jorma Isola; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

4.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

Authors:  M C Paterson; K D Dietrich; J Danyluk; A H Paterson; A W Lees; N Jamil; J Hanson; H Jenkins; B E Krause; W A McBlain
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

5.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

6.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 8.  Follow-up study of HER-2/neu amplification in primary breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors:  Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506

Review 10.  HER-2 and topoisomerase II as predictors of response to chemotherapy.

Authors:  Kathleen I Pritchard; Hans Messersmith; Leela Elavathil; Maureen Trudeau; Frances O'Malley; Bindi Dhesy-Thind
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544
View more
  4 in total

Review 1.  A review of prognostic and predictive biomarkers in breast cancer.

Authors:  Elaheh Tarighati; Hadi Keivan; Hojjat Mahani
Journal:  Clin Exp Med       Date:  2022-01-15       Impact factor: 3.984

Review 2.  The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.

Authors:  Ortensia Ilaria Parisi; Fabrizio Francomano; Marco Dattilo; Francesco Patitucci; Sabrina Prete; Fabio Amone; Francesco Puoci
Journal:  J Funct Biomater       Date:  2022-01-28

Review 3.  Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.

Authors:  Chris Vi; Giovanni Mandarano; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 4.  Embracing Mechanobiology in Next Generation Organ-On-A-Chip Models of Bone Metastasis.

Authors:  Ellen E Slay; Fiona C Meldrum; Virginia Pensabene; Mahetab H Amer
Journal:  Front Med Technol       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.